Age differences in the association of comorbid burden with adverse outcomes in SARS-CoV-2.


Journal

BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548

Informations de publication

Date de publication:
06 07 2021
Historique:
received: 27 10 2020
accepted: 06 06 2021
entrez: 7 7 2021
pubmed: 8 7 2021
medline: 10 7 2021
Statut: epublish

Résumé

Older age and comorbid burden are both associated with adverse outcomes in SARS-CoV-2, but it is not known whether the association between comorbid burden and adverse outcomes differs in older and younger adults. To compare the relationship between comorbid burden and adverse outcomes in adults with SARS-CoV-2 of different ages (18-64, 65-79 and ≥ 80 years). Observational longitudinal cohort study of 170,528 patients who tested positive for SARS-CoV-2 in the US Department of Veterans Affairs (VA) Health Care System between 2/28/20 and 12/31/2020 who were followed through 01/31/2021. Charlson Comorbidity Index (CCI); Incidence of hospitalization, intensive care unit (ICU) admission, mechanical ventilation, and death within 30 days of a positive SARS-CoV-2 test. The cumulative 30-day incidence of death was 0.8% in cohort members < 65 years, 7.1% in those aged 65-79 years and 20.6% in those aged ≥80 years. The respective 30-day incidences of hospitalization were 8.2, 21.7 and 29.5%, of ICU admission were 2.7, 8.6, and 11% and of mechanical ventilation were 1, 3.9 and 3.2%. Median CCI (interquartile range) ranged from 0.0 (0.0, 2.0) in the youngest, to 4 (2.0, 7.0) in the oldest age group. The adjusted association of CCI with all outcomes was attenuated at older ages such that the threshold level of CCI above which the risk for each outcome exceeded the reference group (1st quartile) was lower in younger than in older cohort members (p < 0.001 for all age group interactions). The CCI is calculated based on diagnostic codes, which may not provide an accurate assessment of comorbid burden. Age differences in the distribution and prognostic significance of overall comorbid burden could inform clinical management, vaccination prioritization and population health during the pandemic and argue for more work to understand the role of age and comorbidity in shaping the care of hospitalized patients with SARS-CoV-2.

Sections du résumé

BACKGROUND
Older age and comorbid burden are both associated with adverse outcomes in SARS-CoV-2, but it is not known whether the association between comorbid burden and adverse outcomes differs in older and younger adults.
OBJECTIVE
To compare the relationship between comorbid burden and adverse outcomes in adults with SARS-CoV-2 of different ages (18-64, 65-79 and ≥ 80 years).
DESIGN, SETTING, AND PARTICIPANTS
Observational longitudinal cohort study of 170,528 patients who tested positive for SARS-CoV-2 in the US Department of Veterans Affairs (VA) Health Care System between 2/28/20 and 12/31/2020 who were followed through 01/31/2021.
MEASUREMENTS
Charlson Comorbidity Index (CCI); Incidence of hospitalization, intensive care unit (ICU) admission, mechanical ventilation, and death within 30 days of a positive SARS-CoV-2 test.
RESULTS
The cumulative 30-day incidence of death was 0.8% in cohort members < 65 years, 7.1% in those aged 65-79 years and 20.6% in those aged ≥80 years. The respective 30-day incidences of hospitalization were 8.2, 21.7 and 29.5%, of ICU admission were 2.7, 8.6, and 11% and of mechanical ventilation were 1, 3.9 and 3.2%. Median CCI (interquartile range) ranged from 0.0 (0.0, 2.0) in the youngest, to 4 (2.0, 7.0) in the oldest age group. The adjusted association of CCI with all outcomes was attenuated at older ages such that the threshold level of CCI above which the risk for each outcome exceeded the reference group (1st quartile) was lower in younger than in older cohort members (p < 0.001 for all age group interactions).
LIMITATIONS
The CCI is calculated based on diagnostic codes, which may not provide an accurate assessment of comorbid burden.
CONCLUSIONS
Age differences in the distribution and prognostic significance of overall comorbid burden could inform clinical management, vaccination prioritization and population health during the pandemic and argue for more work to understand the role of age and comorbidity in shaping the care of hospitalized patients with SARS-CoV-2.

Identifiants

pubmed: 34229623
doi: 10.1186/s12877-021-02340-5
pii: 10.1186/s12877-021-02340-5
pmc: PMC8258273
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

415

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI136921
Pays : United States

Références

Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Lancet. 2020 Jun 6;395(10239):1740-1741
pubmed: 32442530
J Am Med Dir Assoc. 2020 Nov;21(11):1555-1559.e2
pubmed: 32978065
Rev Esp Quimioter. 2020 Oct;33(5):369-378
pubmed: 32729288
MMWR Morb Mortal Wkly Rep. 2020 May 08;69(18):545-550
pubmed: 32379729
Ann Intern Med. 2020 Nov 17;173(10):773-781
pubmed: 32783686
N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
J Gen Intern Med. 2020 Aug;35(8):2516-2517
pubmed: 32519326
Int J Epidemiol. 2020 Oct 1;49(5):1468-1481
pubmed: 32887982
Ann Epidemiol. 2020 Jul;47:37-44
pubmed: 32419766
Swiss Med Wkly. 2020 Apr 30;150:w20269
pubmed: 32352150
JAMA Netw Open. 2020 Jun 1;3(6):e2012270
pubmed: 32543702
JAMA Intern Med. 2021 Apr 1;181(4):439-448
pubmed: 33394006
J Am Geriatr Soc. 2020 Jun;68(6):1143-1149
pubmed: 32374466
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Lancet Glob Health. 2020 Aug;8(8):e1003-e1017
pubmed: 32553130
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Int J Public Health. 2020 Jun;65(5):533-546
pubmed: 32451563
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Lancet Glob Health. 2020 Aug;8(8):e1018-e1026
pubmed: 32622400
Eur Geriatr Med. 2020 Oct;11(5):829-841
pubmed: 32671732
Vaccine. 2021 Apr 28;39(18):2517-2525
pubmed: 33824037
J Am Geriatr Soc. 2020 Jun;68(6):1136-1142
pubmed: 32374440
JAMA Netw Open. 2020 Sep 1;3(9):e2022310
pubmed: 32965502
N Engl J Med. 2020 May 21;382(21):2005-2011
pubmed: 32220208
J Infect. 2020 Sep;81(3):411-419
pubmed: 32504743
Ann Intern Med. 2020 Nov 3;173(9):762-763
pubmed: 32698604
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Ann Intern Med. 2020 Nov 17;173(10):782-790
pubmed: 32726151
Am J Public Health. 2008 Jul;98(7):1209-14
pubmed: 18511714
PLoS Med. 2020 Sep 10;17(9):e1003321
pubmed: 32911500
Hypertension. 2020 Aug;76(2):366-372
pubmed: 32564693
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
BMJ Open. 2021 Apr 7;11(4):e047121
pubmed: 33827848
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
PLoS One. 2020 Nov 11;15(11):e0241825
pubmed: 33175863
JAMA Intern Med. 2020 Nov 1;180(11):1436-1447
pubmed: 32667668
J Gen Intern Med. 2020 Jan;35(1):119-125
pubmed: 31667750
Int J Clin Pract. 2021 Apr;75(4):e13858
pubmed: 33237615
JAMA Otolaryngol Head Neck Surg. 2020 Aug 1;146(8):723-728
pubmed: 32556070
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Ann Rheum Dis. 2020 Jul;79(7):859-866
pubmed: 32471903
PLoS One. 2021 Apr 15;16(4):e0249920
pubmed: 33857224
Diabetologia. 2020 Aug;63(8):1500-1515
pubmed: 32472191
Clin Infect Dis. 2021 May 4;72(9):e206-e214
pubmed: 32674114
Int J Med Sci. 2020 Aug 25;17(15):2257-2263
pubmed: 32922189
Ann Intern Med. 2020 Nov 3;173(9):714-720
pubmed: 32698605
Clin Infect Dis. 2020 Sep 28;:
pubmed: 32986102
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Lancet Infect Dis. 2020 Sep;20(9):e238-e244
pubmed: 32628905
J Clin Med. 2020 Sep 28;9(10):
pubmed: 32998337
J Am Geriatr Soc. 2006 Jun;54(6):906-11
pubmed: 16776784
J Gen Intern Med. 2020 Sep;35(9):2801-2803
pubmed: 32583345
Hastings Cent Rep. 2020 May;50(3):61-63
pubmed: 32596888
JAMA. 2020 Jun 2;323(21):2195-2198
pubmed: 32329797
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
JAMA Netw Open. 2021 Apr 1;4(4):e214347
pubmed: 33822066
J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1796-1800
pubmed: 32506122
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
BMJ. 2020 May 22;369:m1985
pubmed: 32444460

Auteurs

A M O'Hare (AM)

Division of Nephrology, Veterans Affairs Puget Sound Healthcare System and University of Washington, 1660 South Columbian Way, Seattle, WA, 98108, USA. Ann.OHare@va.gov.
Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA. Ann.OHare@va.gov.

K Berry (K)

Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.

V S Fan (VS)

Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
Division of Pulmonary and Critical Care, Veterans Affairs Puget Sound Healthcare System and University of Washington, Seattle, WA, USA.

K Crothers (K)

Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
Division of Pulmonary and Critical Care, Veterans Affairs Puget Sound Healthcare System and University of Washington, Seattle, WA, USA.

M C Eastment (MC)

Division of Allergy and Infectious Disease, Veterans Affairs Puget Sound Healthcare System and University of Washington, Seattle, WA, USA.

J A Dominitz (JA)

Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
Division of Gastroenterology, Veterans Affairs Puget Sound Healthcare System and University of Washington, Seattle, WA, USA.

J A Shah (JA)

Division of Allergy and Infectious Disease, Veterans Affairs Puget Sound Healthcare System and University of Washington, Seattle, WA, USA.

P Green (P)

Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.

E Locke (E)

Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.

G N Ioannou (GN)

Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
Division of Gastroenterology, Veterans Affairs Puget Sound Healthcare System and University of Washington, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH